Research Article
Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods
Table 2
CTC positivity (number of cases and percentage) by AdnaTest stratified according to clinical settings and time of analysis.
| | Clinical setting | CTC+ (%) at baseline
(T0) | CTC+ (%) after the 1st cycle of therapy
(T1) | CTC+ (%) after the 2nd cycle of therapy
(T2) |
| | M0 | 4/16 (25.0%) | 9/15 (60.0%) | 10/16 (62.5%) | | M+ | 27/47 (57.4%) | 32/37 (86.5%) | 16/25 (64.0%) | | | 18/33 (54.6%) | 21/26 (80.8%) | 16/25 (64.0%) | | | 9/14 (64.3%) | 11/11 (100%) | — | | Total | 31/63 (49.2%) | 41/52 (78.8%) | 26/41 (63.4%) |
|
|
